drugset

drugset / Trial / NCT05858619

Molecular Signatures of Cutaneous Dupilumab Response

NCT05858619 ↗

Phase 4 Recruiting 15 enrolled University of California, San Francisco

NaSingle-groupOpen-labelBasic science

Summary

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Timeline

Start: 2023-02-01
Primary completion: 2028-02-01
Completion: 2028-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dupilumab	Monoclonal antibody	300 mg	—

Indications